肥胖药物和精确营养:协同干预和综合方法在肥胖管理。

IF 17 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Alessandra Feraco, Elisabetta Camajani, Giovanna Muscogiuri, Luigi Barrea, Annamaria Colao, Massimiliano Caprio
{"title":"肥胖药物和精确营养:协同干预和综合方法在肥胖管理。","authors":"Alessandra Feraco, Elisabetta Camajani, Giovanna Muscogiuri, Luigi Barrea, Annamaria Colao, Massimiliano Caprio","doi":"10.1007/s13679-026-00695-7","DOIUrl":null,"url":null,"abstract":"<p><p>PURPOSE OF THE REVIEW: Obesity represents a major global health challenge associated with substantial metabolic, cardiovascular, and oncologic risk. Recent advances in anti-obesity pharmacotherapies, particularly GLP-1 receptor agonists and the dual GIP/GLP-1 agonist, have redefined clinical management by enabling unprecedented weight loss and significant cardiometabolic benefits. This review summarizes current evidence on how incretin-based therapies affect body composition, eating behavior, and long-term weight trajectories, with a focus on the need for nutritional strategies that support lean mass preservation and durable lifestyle changes. RECENT FINDINGS: Although incretin-based therapied effectively reduce body weight, the resulting weight loss includes a decline in fat-free mass, raising potential concerns about skeletal muscle preservation, particularly in vulnerable populations. Protein-enriched meal replacements (MRs) and structured dietary programs, including very low energy ketogenic therapy (VLEKT), have emerged as practical approaches to improve adherence, enhance fat loss, and stimulate muscle protein synthesis during medication-induced caloric restriction. Several studies indicate that MR-based interventions achieve greater weight loss and metabolic improvements than conventional diets, and that EAA-enriched formulations may provide additional advantages for preserving muscle mass. Combining MRs or VLEKT with incretin-based treatments may offer synergistic advantages by coupling pharmacological appetite regulation with controlled nutrient delivery and behavioral support. Structured nutritional interventions remain essential throughout pharmacotherapy and represent valuable alternatives when medications are discontinued or contraindicated. Overall, integrating incretin-based pharmacotherapy with optimized dietary strategies constitutes an approach to care that may enhance long-term effectiveness, promote nutritional rehabilitation, preserve muscle health, and address the needs of individuals at risk of sarcopenia. </p>","PeriodicalId":10846,"journal":{"name":"Current Obesity Reports","volume":"15 1","pages":""},"PeriodicalIF":17.0000,"publicationDate":"2026-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Obesity medications and precision nutrition: synergistic interventions and integrated approach in obesity management.\",\"authors\":\"Alessandra Feraco, Elisabetta Camajani, Giovanna Muscogiuri, Luigi Barrea, Annamaria Colao, Massimiliano Caprio\",\"doi\":\"10.1007/s13679-026-00695-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>PURPOSE OF THE REVIEW: Obesity represents a major global health challenge associated with substantial metabolic, cardiovascular, and oncologic risk. Recent advances in anti-obesity pharmacotherapies, particularly GLP-1 receptor agonists and the dual GIP/GLP-1 agonist, have redefined clinical management by enabling unprecedented weight loss and significant cardiometabolic benefits. This review summarizes current evidence on how incretin-based therapies affect body composition, eating behavior, and long-term weight trajectories, with a focus on the need for nutritional strategies that support lean mass preservation and durable lifestyle changes. RECENT FINDINGS: Although incretin-based therapied effectively reduce body weight, the resulting weight loss includes a decline in fat-free mass, raising potential concerns about skeletal muscle preservation, particularly in vulnerable populations. Protein-enriched meal replacements (MRs) and structured dietary programs, including very low energy ketogenic therapy (VLEKT), have emerged as practical approaches to improve adherence, enhance fat loss, and stimulate muscle protein synthesis during medication-induced caloric restriction. Several studies indicate that MR-based interventions achieve greater weight loss and metabolic improvements than conventional diets, and that EAA-enriched formulations may provide additional advantages for preserving muscle mass. Combining MRs or VLEKT with incretin-based treatments may offer synergistic advantages by coupling pharmacological appetite regulation with controlled nutrient delivery and behavioral support. Structured nutritional interventions remain essential throughout pharmacotherapy and represent valuable alternatives when medications are discontinued or contraindicated. Overall, integrating incretin-based pharmacotherapy with optimized dietary strategies constitutes an approach to care that may enhance long-term effectiveness, promote nutritional rehabilitation, preserve muscle health, and address the needs of individuals at risk of sarcopenia. </p>\",\"PeriodicalId\":10846,\"journal\":{\"name\":\"Current Obesity Reports\",\"volume\":\"15 1\",\"pages\":\"\"},\"PeriodicalIF\":17.0000,\"publicationDate\":\"2026-02-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Obesity Reports\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s13679-026-00695-7\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Obesity Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13679-026-00695-7","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

综述的目的:肥胖是一项主要的全球性健康挑战,与大量代谢、心血管和肿瘤风险相关。抗肥胖药物治疗的最新进展,特别是GLP-1受体激动剂和双重GIP/GLP-1激动剂,通过实现前所未有的体重减轻和显著的心脏代谢益处,重新定义了临床管理。这篇综述总结了目前关于肠促胰岛素治疗如何影响身体组成、饮食行为和长期体重轨迹的证据,重点是支持瘦质量保存和持久生活方式改变的营养策略的需要。最近的研究发现:尽管以肠促胰岛素为基础的治疗有效地减轻了体重,但由此产生的体重减轻包括无脂肪量的下降,这引起了对骨骼肌保存的潜在担忧,特别是在弱势人群中。富含蛋白质的代餐(MRs)和结构化饮食计划,包括极低能量生酮疗法(VLEKT),已经成为在药物诱导的热量限制期间提高依从性、促进脂肪减少和刺激肌肉蛋白质合成的实用方法。几项研究表明,与传统饮食相比,基于核磁共振的干预措施可以实现更大的体重减轻和代谢改善,并且富含eaa的配方可能为保持肌肉质量提供额外的优势。将MRs或VLEKT与以肠促胰岛素为基础的治疗相结合,可能通过将药理食欲调节与控制的营养输送和行为支持相结合,提供协同优势。在整个药物治疗过程中,有组织的营养干预仍然是必不可少的,当药物停止或禁忌时,营养干预是有价值的替代方案。总之,将肠促胰岛素为基础的药物治疗与优化的饮食策略相结合,可以提高长期疗效,促进营养康复,保持肌肉健康,并解决肌少症风险个体的需求。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Obesity medications and precision nutrition: synergistic interventions and integrated approach in obesity management.

PURPOSE OF THE REVIEW: Obesity represents a major global health challenge associated with substantial metabolic, cardiovascular, and oncologic risk. Recent advances in anti-obesity pharmacotherapies, particularly GLP-1 receptor agonists and the dual GIP/GLP-1 agonist, have redefined clinical management by enabling unprecedented weight loss and significant cardiometabolic benefits. This review summarizes current evidence on how incretin-based therapies affect body composition, eating behavior, and long-term weight trajectories, with a focus on the need for nutritional strategies that support lean mass preservation and durable lifestyle changes. RECENT FINDINGS: Although incretin-based therapied effectively reduce body weight, the resulting weight loss includes a decline in fat-free mass, raising potential concerns about skeletal muscle preservation, particularly in vulnerable populations. Protein-enriched meal replacements (MRs) and structured dietary programs, including very low energy ketogenic therapy (VLEKT), have emerged as practical approaches to improve adherence, enhance fat loss, and stimulate muscle protein synthesis during medication-induced caloric restriction. Several studies indicate that MR-based interventions achieve greater weight loss and metabolic improvements than conventional diets, and that EAA-enriched formulations may provide additional advantages for preserving muscle mass. Combining MRs or VLEKT with incretin-based treatments may offer synergistic advantages by coupling pharmacological appetite regulation with controlled nutrient delivery and behavioral support. Structured nutritional interventions remain essential throughout pharmacotherapy and represent valuable alternatives when medications are discontinued or contraindicated. Overall, integrating incretin-based pharmacotherapy with optimized dietary strategies constitutes an approach to care that may enhance long-term effectiveness, promote nutritional rehabilitation, preserve muscle health, and address the needs of individuals at risk of sarcopenia.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current Obesity Reports
Current Obesity Reports Medicine-General Medicine
CiteScore
16.40
自引率
1.10%
发文量
25
期刊介绍: The main objective of Current Obesity Reports is to provide expert review articles on recent advancements in the interdisciplinary field of obesity research. Our aim is to offer clear, insightful, and balanced contributions that will benefit all individuals involved in the treatment and prevention of obesity, as well as related conditions such as cardiovascular diseases, endocrine disorders, gynecological issues, cancer, mental health, respiratory complications, and rheumatological diseases. We strive to redefine the way knowledge is expressed and provide organized content for the benefit of our readership.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书